This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by McGrath, H. Articles by Lee, F. Search for Related Content PubMed PubMed Citation Articles by McGrath, H., JR Articles by Lee, F. Social Bookmarking                         What's this?

Review : Ultraviolet-A1 (340-400 nm) irradiation therapy in systemic lupus erythematosus

Department of Medicine, Louisiana State University Medical Center, New Orleans

P. Martínez-Osuna

Department of Medicine, Louisiana State University Medical Center, New Orleans

FA Lee

Tulane/LSU General Clinical Research Center, Charity Hospital, New Orleans LA, USA

Ultraviolet-A1 (UV-A1) wavelengths have been found effective in mitigating signs and symp toms of disease activity in systemic lupus erythematosus (SLE) but studies have been uncon trolled. To rigorously assess the effectiveness and safety of daily low-dose UV-A1 irradiation as a therapeutic agent in this disorder we enrolled 26 women with SLE in an 18-week two-phase study. During the initial six-week prospective, double-blind, placebo-controlled phase, the patients were divided into two groups; Group A was exposed to 60 kJ/m ² of UV-A1 (340-400 nm) irradiation within a sunbed five days a week for three weeks and Group B was exposed for an equal amount of time to visible light of greater than > 430 nm (placebo). Each group was then crossed over for exposure to the other source for three weeks. During the second phase - 12 weeks - patients and physicians were unblinded and patients were irradiated with progressively decreasing levels of UV-A1 only.

Twenty-five patients completed the six-week placebo-controlled phase of the study and eighteen patients participated for the entire 18 weeks. In Group A the systemic lupus activ ity measure (SLAM) score improved significantly after three weeks of five-day-a-week UV-A1 irradiation (P < 0.05), regressing to baseline during the three weeks of placebo irra diation. Improvement recurred and progressed with six weeks of three-day-a-week UV-A1 irradiation (P < 0.05). Group B patients responded negligibly to the three weeks of visible light, more sharply to UV-A1, and as with Group A, maximally to the six weeks of three- day-a-week UV-A1 (P < 0.01). With twice- and then once-weekly UV-A1 irradiation the SLAM scores worsened slightly.

All patients decreased their drug use. Anti-double-stranded DNA antibodies (anti- dsDNA) decreased significantly (P < 0.05) and anti-nuclear antibodies non-significantly. Side effects were negligible. Visible light had no significant effect. In conclusion, low-dose UV-A1 irradiation effectively, comfortably, and without apparent toxicity diminished signs and symptoms of disease activity in SLE.

Key Words: systemic lupus erythematosus • ultraviolet-A1 • therapy • ultraviolet therapy

Lupus, Vol. 5, No. 4, 269-274 (1996)
DOI: 10.1177/096120339600500405


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. Y. Yuen and J. E. Pope Learning from past mistakes: assessing trial quality, power and eligibility in non-renal systemic lupus erythematosus randomized controlled trials Rheumatology, September 1, 2008; 47(9): 1367 - 1372. [Abstract] [Full Text] [PDF]

				S. Pavel Light therapy (with UVA-1) for SLE patients: is it a good or bad idea? Rheumatology, June 1, 2006; 45(6): 653 - 655. [Full Text] [PDF]

				H McGrath Jr Elimination of anticardiolipin antibodies and cessation of cognitive decline in a UV-A1-irradiated systemic lupus erythematosus patient Lupus, October 1, 2005; 14(10): 859 - 861. [Abstract] [PDF]

				A. Szegedi, E. Simics, M. Aleksza, I. Horkay, K. Gaal, S. Sipka, J. Hunyadi, and E. Kiss Ultraviolet-A1 phototherapy modulates Th1/Th2 and Tc1/Tc2 balance in patients with systemic lupus erythematosus Rheumatology, July 1, 2005; 44(7): 925 - 931. [Abstract] [Full Text] [PDF]

				T Hasan, M Pertovaara, U Yli-Kerttula, T Luukkaala, and M Korpela Seasonal variation of disease activity of systemic lupus erythematosus in Finland: a 1 year follow up study Ann Rheum Dis, November 1, 2004; 63(11): 1498 - 1500. [Abstract] [Full Text] [PDF]

				M. C. A. Polderman, S. le Cessie, T. W. J. Huizinga, and S. Pavel Efficacy of UVA-1 cold light as an adjuvant therapy for systemic lupus erythematosus Rheumatology, November 1, 2004; 43(11): 1402 - 1404. [Abstract] [Full Text] [PDF]

				Y Menon, K McCarthy, and H McGrath Jr Reversal of brain dysfunction with UV-A1 irradiation in a patient with systemic lupus Lupus, June 1, 2003; 12(6): 479 - 482. [Abstract] [PDF]

				V N Foltyn and T D Golan In vitro ultraviolet irradiation induces pro-inflammatory responses in cells from premorbid SLE mice Lupus, April 1, 2001; 10(4): 272 - 283. [Abstract] [PDF]

				T P Millard and J L. Hawk Ultraviolet therapy in lupus Lupus, March 1, 2001; 10(3): 185 - 187. [Abstract] [PDF]

				M C A Polderman, T W J Huizinga, S Le Cessie, and S Pavel UVA-1 cold light treatment of SLE: a double blind, placebo controlled crossover trial Ann Rheum Dis, February 1, 2001; 60(2): 112 - 115. [Abstract] [Full Text] [PDF]

				T P Millard, J L M Hawk, and J M Mcgregor Photosensitivity in lupus Lupus, January 1, 2000; 9(1): 3 - 10. [Abstract] [PDF]

				M Corzillius and S-C Bae Methodological issues of corticosteroid use in SLE clinical trials Lupus, October 1, 1999; 8(8): 692 - 697. [Abstract] [PDF]

				H. McGrath JR Prospects for UV-Al therapy as a treatment modality in cutaneous and systemic LE Lupus, January 1, 1997; 6(2): 209 - 217. [PDF]